$1.38
+0.07(5.34%)
Mkt Cap $119M
$0.65
$2.95
52-Week Range
At a Glance
AI-generatedMilestone Pharmaceuticals Inc.
8-K
Milestone Pharmaceuticals Inc. reported Q4 and full year 2025 financial results, including $1.5 million revenue, $63.1 million net loss, and $106.0 million cash as of December 31, 2025. The company provided updates on the CARDAMYST commercial launch following FDA approval on December 12, 2025, and received $75 million from RTW Royalty financing.$119M
Market Cap
$2M
Revenue
-$64M
Net Income
Employees33
Fundamentals
How The Business Makes Money
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001408443
ISINCA59935V1076
CUSIP59935V107
Phone15143360444
Address1111 Dr. Frederik-Philips Boulevard, Montreal, QC, H4M 2X6, CA
SEC EDGAR